Nuvalent Inc (NUVL)
68.00
-0.57
(-0.83%)
USD |
NASDAQ |
May 08, 10:27
Nuvalent Cash from Investing (TTM): -143.53M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -143.53M |
September 30, 2023 | -152.67M |
June 30, 2023 | -173.50M |
March 31, 2023 | -150.98M |
December 31, 2022 | -10.66M |
September 30, 2022 | -108.72M |
Date | Value |
---|---|
June 30, 2022 | -182.86M |
March 31, 2022 | -206.97M |
December 31, 2021 | -220.03M |
September 30, 2021 | -56.57M |
June 30, 2021 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-220.03M
Minimum
Dec 2021
--
Maximum
Jun 2021
-127.86M
Average
-150.98M
Median
Mar 2023
Cash from Investing (TTM) Benchmarks
Geron Corp | 32.62M |
Verastem Inc | -44.45M |
Karyopharm Therapeutics Inc | 7.94M |
Syndax Pharmaceuticals Inc | 117.61M |
AnaptysBio Inc | 144.75M |